Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/14/2012

nt expenses are primarily costs relating to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD.

Cash Position
Palatin's cash and cash equivalents were $33.5 million as of September 30, 2012, compared to $3.8 million at June 30, 2012, with current liabilities of $1.6 million as of September 30, 2012 compared to $3.5 million as of June 30, 2012.

Palatin believes that its existing capital resources will be adequate to fund its currently planned operations, including completing analysis of results of the Company's Phase 2B clinical trial with bremelanotide for FSD, submitting an end-of-phase 2 meeting request to the FDA, and commencing Phase 3 activities, through at least calendar year 2013.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on November 14, 2012 at 11:00 a.m. Eastern Time to discuss the results of operations and an update on corporate developments in greater detail.  Individuals interested in listening to the conference call live can dial 1-888-428-9490 (domestic) or 1-719-325-2354 (international), pass code 9649528.  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.  A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 9649528.  The webcast and telephone replay will be available through November 20, 2012. 

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing co
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... the forefront of diagnostics today, with imaging techniques ... scanning, and NMR (nuclear magnetic resonance) increasing steeply ... of image resolution and quality still limit these ... A solution is hyperpolarization, which involves injecting the ... by following the distribution and fate of specific ...
(Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
(Date:9/29/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that its three Promissory Note holders, two of ... 100,000 each in July 2014 for a total of ... Coupons converted into 3,500,001 restricted common shares. Notes were ... the Note and the coupon were convertible into common ...
(Date:9/29/2014)... batteries are efficient but involve a range of ... (lucerne seed) and pine resin and a clever ... with a highly interesting alternative. Their study will ... ChemSusChem . , ,We think our discovery can ... for the batteries of the future, says Daniel ...
Breaking Biology Technology:A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Smart, eco-friendly new battery to solve problems 2
... that a new market research report is available in its ... http://www.reportlinker.com/p0313372/Industrial-Biotechnology-China-News-1009.html China is ... become the second largest world,s economy. China,s economy ... 30 years and may keep growing at a high rate ...
... of TOGS™ 9000 ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... Consulting Ltd offers new cutting-edge market research reports on ... Prions - Market Report. This ... Deactivation technologies, Post Mortem Testing for BSE and Prion ... test Kits, Deactivation /Inactivation technologies, Reagents and Services. The ...
Cached Biology Technology:Reportlinker Adds Industrial Biotechnology China News 1009 2Reportlinker Adds Industrial Biotechnology China News 1009 3BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000 2BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000 3BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000 4BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000 5BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000 6BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000 7In-demand Contemporary Research Reports on Biotechnology Markets Available at MCGroup.co.uk 2In-demand Contemporary Research Reports on Biotechnology Markets Available at MCGroup.co.uk 3In-demand Contemporary Research Reports on Biotechnology Markets Available at MCGroup.co.uk 4
(Date:9/30/2014)... strawberries all have in common? Unlike most eukaryotic ... are diploid, these organisms are all polyploid, meaning they ... salmon have 3 and 4 sets of chromosomes, respectively, ... surprising, in fact most plant species are polyploid. Polyploidy, ... ago, but only recently, with the development of molecular ...
(Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
(Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Contaminated water linked to pregnancy complications, BU study finds 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... political candidate,s electoral victory or defeat is influenced by ... to new Stanford University studies of the most recent ... coordinated effort looking at whether candidates, statements on climate ... of communication and of political science at Stanford, who ...
... has overcome a major hurdle in the quest to ... make the production of gasoline, plastics and various chemicals ... led by chemical engineering and materials science professor Michael ... is published in the most recent issue of the ...
... University are studying how two types of nanoscale structures ... colors. The researchers are hoping that by borrowing these ... produce new types of lasersones that can assemble themselves ... at the Optical Society,s (OSA) Annual Meeting, Frontiers in ...
Cached Biology News:Stanford researchers examine impact of 'green politics' on recent national elections 2Stanford researchers examine impact of 'green politics' on recent national elections 3Minnesota discovery could make fuel and plastics production more energy efficient and cost effective 2Borrowing from brightly-colored birds: Physicists develop lasers inspired by nature 2
... ATPase α-1, clone C464.6 GenBank Accession ... Na + /K + ATPase isolated ... medulla Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M ... routinely evaluated in immunoblot on rat brain ...
PSGL-1 (215)...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Biology Products: